For researchers submitting trial data to ClinicalTrials.gov, the Adverse Events module is one of four mandatory results sections. It requires reporting in three primary categories: All-Cause Mortality: A table tracking all deaths that occurred during the study, regardless of cause. Serious Adverse Events (SAEs): A tabular summary of events resulting in death, life-threatening conditions, hospitalization, or significant disability. Other Adverse Events: A table for non-serious events that exceed a specific frequency threshold, such as 5% within any study arm.
Adverse Events Module path is as follows:
Study -> Results Section -> Adverse Events Module -> Event Groups
Study -> Results Section -> Adverse Events Module -> Serious Events
Study -> Results Section -> Adverse Events Module -> Other Events
| Title | Description | Deaths # Affected | Deaths # At Risk | Serious # Affected | Serious # At Risk | Other # Affected | Other # At Risk | View |
|---|---|---|---|---|---|---|---|---|
| Desloratadine 5 mg | Participants receive one desloratadine 5 mg tablet and one placebo tablet orally once daily for up to 2 weeks | None | None | 1 | 202 | 11 | 202 | View |
| Desloratadine 10 mg | Participants receive two desloratadine 5 mg tablets orally once daily for up to 2 weeks | None | None | 0 | 203 | 17 | 203 | View |
| Placebo | Participants receive two placebo tablets orally once daily for up to 2 weeks | None | None | 0 | 201 | 9 | 201 | View |
| Term | Type | Organ System | Vocab | View |
|---|---|---|---|---|
| Epilepsy | SYSTEMATIC_ASSESSMENT | Nervous system disorders | MedDRA 16.1 | View |
| Term | Type | Organ System | Vocab | View |
|---|---|---|---|---|
| Nasphopharyngitis | SYSTEMATIC_ASSESSMENT | Infections and infestations | MedDRA 16.1 | View |